Venetoclax/Decitabine for Young Adults With Newly Diagnosed ELN Adverse-Risk AML: Phase II Trial Interim Analysis

Source: 2021 American Society of Hematology Annual Meeting*
Download Slideset
December 11-14, 2021; Atlanta, Georgia
In young adults with newly diagnosed adverse-risk AML, venetoclax plus decitabine was associated with a composite CR rate of 76% and in a historical comparison showed a better efficacy and safety profile than cytarabine/idarubicin.
Format: Microsoft PowerPoint (.ppt)
File Size: 495 KB
Released: December 13, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings